Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2Q28FjU
from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2Q28FjU